No Data
Botuo Biotech: Botuo Biotech 2024 Annual Performance Report Announcement
Botuo Biotech 2024 Annual Results Report Announcement
Botao Biotechnology (688767.SH): Director and senior management personnel Gao Hongmei plans to reduce shareholding by no more than 0.56 million shares.
On February 6, Gelonghui reported that Botou Biotechnology (688767.SH) announced that it recently received a "Shareholding Reduction Plan Notification Letter" from Ms. Gao Hongmei, a Director and senior management personnel. Due to personal funding needs, Ms. Gao Hongmei intends to reduce her shareholding by no more than 560,000 shares through block trading or centralized bidding, which accounts for no more than 0.5250% of the company's total share capital. The reduction period will be within three months starting from 15 trading days after the announcement of this shareholding reduction plan.
Botuo Biotech: Botuo Biotech\'s 2024 annual results forecast
Botuo Biotech 2024 Annual Results Forecast
Botao Biotechnology (688767.SH): Net income is expected to increase by approximately 59.47% in 2024.
On January 23, Gelonghui reported that Botao Biotechnology (688767.SH) announced its annual earnings forecast for 2024. According to preliminary calculations by the finance department, it is expected that the net income attributable to the parent company's owners will be around 170 million yuan in 2024, an increase of approximately 59.47% year-on-year. The net income attributable to the parent company's owners after deducting non-recurring gains and losses is expected to be around 119 million yuan, an increase of approximately 49.83% year-on-year. The company continues to focus on the POCT in-vitro diagnostics sub-industry, effectively grasping customer needs and actively expanding domestic and international markets.